Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.

doi:10.1158/2159-8290.CD-24-0027

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.

Cancer discovery - 3 Jun 2024

Jiang Jingjing, Jiang Lingyan, Maldonato Benjamin J, Wang Yingyun, Holderfield Matthew, Aronchik Ida, Winters Ian P, Salman Zeena, Blaj Cristina, Menard Marie, Brodbeck Jens, Chen Zhe, Wei Xing, Rosen Michael J, Gindin Yevgeniy, Lee Bianca J, Evans James W, Chang Stephanie, Wang Zhican, Seamon Kyle J, Parsons Dylan, Cregg James, Marquez Abby, Tomlinson Aidan C A, Yano Jason K, Knox John E, Quintana Elsa, Aguirre Andrew J, Arbour Kathryn C, Reed Abby, Gustafson W Clay, Gill Adrian L, Koltun Elena S, Wildes David, Smith Jacqueline A M, Wang Zhengping, Singh Mallika

Abstract excerpt

RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Guanosine Triphosphate

Share to Lung Neoplasms

Share to Neoplasms

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38593348
DOI: 10.1158/2159-8290.CD-24-0027
PMCID: PMC11149917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.PMID 38593348Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Semantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read ↗

Drugging the Undruggable: Advances on RAS Targeting in Cancer.Semantic proximity Read ↗

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Semantic proximity Read ↗

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Emerging RAS-directed therapies for cancerSemantic proximity Read ↗

The complex journey of targeting RAS in oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.